Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced parkinson's disease mouse model

Neurochemical Research

Volumn 36, Issue 12, 2011, Pages 2244-2249

  Kabuto, Hideaki ^a   Yamanushi, Tomoko T ^a  

^a KAGAWA PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

Antioxidant; Dopamine; Eugenol; L DOPA; Parkinson's disease; Zingerone

Indexed keywords

ASCORBIC ACID; CATALASE; DOPAMINE; EUGENOL; GLUTATHIONE PEROXIDASE; LEVODOPA; LIPID; OXIDOPAMINE; SUPEROXIDE DISMUTASE; ZINGERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFICACY; ENZYME INHIBITION; LIPID PEROXIDATION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPLETION; SINGLE DRUG DOSE;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; CATALASE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; EUGENOL; FREE RADICAL SCAVENGERS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GUAIACOL; LEVODOPA; MALE; MICE; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; SUPEROXIDE DISMUTASE;

ANIMALIA; RODENTIA; ZINGIBER OFFICINALE;

EID: 80755139522     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0548-5     Document Type: Article

References (30)

1. T Kondo 1996 Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection Ann NY Acad Sci 786 206 216 8687020 10.1111/j.1749-6632.1996.tb39063.x 1:CAS:528:DyaK28XkvFCmsrg%3D
2. RJ Tolwani MW Jakowec GM Petzinger, et al. 1999 Experimental models of Parkinson's disease: insights from many models Lab Anim Sci 49 363 371 10480640 1:STN:280:DyaK1MvgvVGitQ%3D%3D (Pubitemid 29411753)
3. R Andrew DG Watson SA Best, et al. 1993 The determination of hydroxydopaminea and other trace animals in the urine of Parkinsonian patients and normal controls Neurochem Res 18 1175 1177 8255370 10.1007/BF00978370 1:CAS:528:DyaK2cXitlequw%3D%3D (Pubitemid 23306353)
4. Y Glinka M Gassen MBH Youdim 1997 Mechanism of 6-hydroxydopamine neurotoxicity J Neural Transm Suppl 50 55 66 9120425 1:STN:280: DyaK2s7ptFKrtA%3D%3D (Pubitemid 27055928)
5. R Kumar AK Agarwal PK Seth 1995 Free radical-generated neurotoxicity of 6-hydroxydopamine J Neurochem 64 1703 1707 7891098 10.1046/j.1471-4159.1995. 64041703.x 1:CAS:528:DyaK2MXksVKit74%3D
6. H Kabuto I Yokoi IE Iwata, et al. 1999 EPC-K1, a hydroxyl radical scavenger, prevents 6-hydroxydopamine-induced dopamine depression in the mouse striatum by up-regulation of catalase activity Neurochem Res 24 1543 1548 10591404 10.1023/A:1021152115752 1:CAS:528:DyaK1MXnsFSjurg%3D
7. H Kabuto M Nishizawa M Tada, et al. 2005 Zingerone [4-(4-hydroxy-3- methoxyphenyl)-2-butanone] prevents 6-hydroxydopamine-induced dopamine depression in mouse striatum and increases superoxide scavenging activity in serum Neurochem Res 30 325 332 16018576 10.1007/s11064-005-2606-3 1:CAS:528:DC%2BD2MXksl2gsLo%3D (Pubitemid 40880808)
8. H Kabuto M Tada M Kohno 2007 Eugenol [2-methoxy-4-(2-propenyl)phenol] prevents 6-hydroxydopamine-induced dopamine depression and lipid peroxidation inductivity in mouse striatum Biol Pharm Bull 30 423 427 17329831 10.1248/bpb.30.423 1:CAS:528:DC%2BD2sXkvVSnt78%3D (Pubitemid 46355914)
9. M Ito K Murakami M Yoshino 2005 Antioxidant action of eugenol compounds: role of metal ion in the inhibition of lipid peroxidation Food Chem Toxicol 43 461 466 15680683 10.1016/j.fct.2004.11.019 1:CAS:528:DC%2BD2MXos1Sgtw%3D%3D (Pubitemid 40170480)
10. E Nagababu N Lakshmaiah 1992 Inhibitory effect of eugenol on non-enzymatic lipid peroxidation in rat river mitochondria Biochem Pharmacol 43 2393 2400 1319160 10.1016/0006-2952(92)90318-D 1:CAS:528:DyaK38XltVChsr4%3D
11. AC Reddy BR Lokesh 1992 Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes Mol Cell Biochem 111 117 124 1588934 1:CAS:528:DyaK38Xkt1Cru7o%3D
12. TP Krishnakantha BR Lokesh 1993 Scavenging of superoxide anions by spice principles Indian J Biochem Biophys 30 133 134 8394839 1:CAS:528: DyaK3sXmt1Gju78%3D
13. N Ogawa 1994 Levodopa and dopamine agonists in the treatment of Parkinson's diseases: advantages and disadvantages Eur Neurol Suppl 34 320 328
14. LW Oberley DR Spitz 1984 Assays of superoxide dismutase activity in tumor tissue Method Enzymol 105 457 464 10.1016/S0076-6879(84)05064-3 1:CAS:528:DyaL2cXltVKisbk%3D (Pubitemid 14165412)
15. H Aebi 1984 Catalase in vitro Method Enzymol 105 121 126 10.1016/S0076-6879(84)05016-3 1:CAS:528:DyaL2cXltVKis7s%3D
16. OJ Lowry NJ Rosebrough AL Farr, et al. 1951 Protein measurement with folin-phenol reagent J Biol Chem 193 265 275 14907713 1:CAS:528: DyaG38XhsVyrsw%3D%3D
17. DT Dexter FR Wells AJ Lees, et al. 1989 Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease J Neurochem 52 1830 1836 2723638 10.1111/j.1471-4159.1989.tb07264.x 1:CAS:528:DyaL1MXkslGrs7k%3D (Pubitemid 19140770)
18. LM Ambani MH Van Woert S Murphy 1975 Brain peroxidase and catalase in Parkinson disease Arch Neurol 32 114 118 1122174 1:CAS:528:DyaE2MXht1aru7o%3D
19. SJ Kish C Morito O Hornykiewicz 1985 Glutathion peroxidase activity in Parkinson's diseases Neurosci Lett 58 343 346 4047494 10.1016/0304-3940(85) 90078-3 1:CAS:528:DyaL2MXlsFymsr0%3D (Pubitemid 15230680)
20. P Riederer E Sofic WD Rausch, et al. 1989 Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains J Neurochem 52 515 520 2911028 10.1111/j.1471-4159.1989.tb09150.x 1:CAS:528:DyaL1MXhtFals78%3D (Pubitemid 19037617)
21. CW Olanow 1993 A radical hypothesis for neurodegeneration Trends Neurosci 16 439 444 7507613 10.1016/0166-2236(93)90070-3 1:CAS:528:DyaK2cXltFKqsw%3D%3D (Pubitemid 23313517)
22. JD Adams IN Odunze 1991 Oxygen free radicals and Parkinson's diseases Free Radical Biol Med 10 161 169 10.1016/0891-5849(91)90009-R 1:CAS:528:DyaK3MXkvFSjsr8%3D (Pubitemid 121003223)
23. N Ogawa R Edamatsu K Mizukawa, et al. 1993 Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa Adv Neurol 60 242 250 8380518 1:CAS:528:DyaK3sXkt1Sgsbk%3D
24. N Ogawa M Asanuma Y Kondo, et al. 1994 Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine Neurosci Lett 171 55 58 8084500 10.1016/0304-3940(94)90603-3 1:CAS:528:DyaK2cXlt1Cqtbs%3D (Pubitemid 124016481)
25. JL Cadet M Katz V Jackson-Lewis, et al. 1989 Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence Brain Res 476 10 15 2492442 10.1016/0006-8993(89)91530-8 1:CAS:528:DyaL1MXlt1Gktw%3D%3D (Pubitemid 19006358)
26. BN Rao BS Rao 2010 Antagonistic effects of zingerone, a phenolic alkanone against radiation-induced cytotoxicity, genotoxicity, apoptosis and oxidative stress in Chinese hamster lung fibroblast cells growing in vitro Mutagenesis 25 577 587 20713432 10.1093/mutage/geq043 1:CAS:528:DC%2BC3cXhsVSltb7P
27. V Calabrese C Comelius A Trovato M Cavallaro, et al. 2010 The hermetic role of dietary antioxidants in free radical-related diseases Curr Pharm Des 16 877 883 20388101 10.2174/138161210790883615 1:CAS:528:DC%2BC3cXhtlCqtbfO
28. BB Aggarwal AB Kunnumakkara KB Harikumar, et al. 2008 Potential of spice-derived phytochemicals for cancer prevention Planta Med 74 1560 1569 18612945 10.1055/s-2008-1074578 1:CAS:528:DC%2BD1cXhtl2hsb3P
29. S Hasana-Ranjbar B Larijani M Abdollahi 2009 A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases Inflamm Allergy Drug Targets 8 2 10 10.2174/187152809787582561
30. JK Kundu HK Na YJ Surh 2009 Ginger-derived phenolic substances with cancer preventive and therapeutic potential Forum Nutr 61 182 192 19367122 10.1159/000212750 1:CAS:528:DC%2BD1MXhtFegtr%2FP